Methods for the prophylaxis and treatment of obesity and related conditions and disorders
Patent Information
- Application Number
- AU2025211528
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-01-12
- Filing Date
- 2025-01-22
- Publication Date
- 2026-09-10
AI Technical Summary
Current treatments for obesity and metabolic disorders, such as obesity-related diabetes, often result in modest weight loss that is difficult to maintain, and there is a need for more effective pharmaceutical interventions that can achieve significant and sustained weight loss while improving metabolic health markers.
The use of cyclic Prolyl Glycine (cPG) compounds, optionally combined with GLP-1 agonists like tirzepatide, semaglutide, or liraglutide, administered orally or subcutaneously, to regulate IGF-1 and GLP-1 signaling pathways, reducing food intake, inducing satiety, and improving glycemic control.
The combination therapy with cPG and GLP-1 agonists achieves significant and sustained weight loss, improves metabolic health markers, and reduces plasma and liver triglycerides, demonstrating potential synergy in treating obesity and diabetes.
Smart Images

Figure 00000000_0000_ABST
